279 related articles for article (PubMed ID: 31496264)
1. In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor.
Colling ME; Friedman KD; Dzik WH
Clin Appl Thromb Hemost; 2019; 25():1076029619873976. PubMed ID: 31496264
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
3. A comparative in vitro evaluation of six von Willebrand factor concentrates.
Lethagen S; Carlson M; Hillarp A
Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
[TBL] [Abstract][Full Text] [Related]
4. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
5. Characterization of von Willebrand factor in factor VIII concentrates.
Fricke WA; Yu MY
Am J Hematol; 1989 May; 31(1):41-5. PubMed ID: 2495715
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
[TBL] [Abstract][Full Text] [Related]
7. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies.
Favaloro EJ; Oliver S; Mohammed S; Vong R
Haemophilia; 2020 May; 26(3):503-512. PubMed ID: 32159272
[TBL] [Abstract][Full Text] [Related]
8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
11. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis.
Metzner HJ; Hermentin P; Cuesta-Linker T; Langner S; Müller HG; Friedebold J
Haemophilia; 1998; 4 Suppl 3():25-32. PubMed ID: 10028315
[TBL] [Abstract][Full Text] [Related]
12. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
Favaloro EJ; Bukuya M; Martinelli T; Tzouroutis J; Duncan E; Welldon K; Collecutt M; Aumann H; Thom J; Gilmore G
Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.
Mannucci PM; Tenconi PM; Castaman G; Rodeghiero F
Blood; 1992 Jun; 79(12):3130-7. PubMed ID: 1596562
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of a recombinant von Willebrand factor drug candidate.
Turecek PL; Schrenk G; Rottensteiner H; Varadi K; Bevers E; Lenting P; Ilk N; Sleytr UB; Ehrlich HJ; Schwarz HP
Semin Thromb Hemost; 2010 Jul; 36(5):510-21. PubMed ID: 20635317
[TBL] [Abstract][Full Text] [Related]
15. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
Auerswald G; Kreuz W
Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
[TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
17. Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease.
Gritsch H; Schrenk G; Weinhappl N; Mellgård B; Ewenstein B; Turecek PL
J Blood Med; 2022; 13():649-662. PubMed ID: 36405429
[TBL] [Abstract][Full Text] [Related]
18. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
19. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.
Federici AB; Mannucci PM
Haemophilia; 1998; 4 Suppl 3():7-10. PubMed ID: 10028312
[TBL] [Abstract][Full Text] [Related]
20. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]